In the third quarter, the number of the patent announcement by pharmaceutical and bio companies decreased significantly.
According to Newsmp’s tally of patent disclosures in the third quarter through the DART (Disclaimer of Liability & Use/Accuracy of Information), patent disclosures in all industries totaled 130 cases, up slightly from 126 cases year-on-year and 122 cases in the second quarter.
On the other hand, the number of patent disclosures by medical materials and pharmaceuticals manufactures in the third quarter totaled 22 cases, down about 40% from 36 cases in the second quarter and more than 20% from 28 cases in the same period last year.
In particular, a total of 15 companies announced patents during this period, and none of them were traditional pharmaceutical companies.
Of the 15 companies, only four have made patent disclosures more than once.
OliPass, PanGen Biotech, and FutureChem formed a leading group by disclosing three patent cases each.
They accounted for nearly half of all patent announcements by medical materials and pharmaceuticals manufactures.
InnoTherapy has published two patents, and Kang Stem Biotech, Bio Solution, SCM LifeScience, ABL Bio, ISU abxis, Geno Focus, Genomictree, Genome & Co., Clinomics, Tego Science, and Pharmabcine disclosed one case.
